Abstract Number: 2134 • 2015 ACR/ARHP Annual Meeting
Metabolic Reprogramming in the Inflamed Joint Inhibits Pro-Inflammatory Mechanisms
Background/Purpose: To examine the relationship between synovial hypoxia, cellular bioenergetics and mitochondrial dysfunction with synovial inflammation. Methods: Primary RASFC were cultured with 3% hypoxia, DMOG…Abstract Number: 2135 • 2015 ACR/ARHP Annual Meeting
miRNA-223 Delivery to Synovial Fibroblasts Via Monocyte-Derived Extracellular Vesicles Promotes Their Proliferation
Background/Purpose: Recently, it was shown that extracellular vesicles (EV) convey microRNAs (miR) from platelets to endothelial cells1and regulate recipient cell gene expression. Interaction of synovial…Abstract Number: 2136 • 2015 ACR/ARHP Annual Meeting
Identification of Synovial Fibroblast Subsets That Define Pathology in Rheumatoid Arthritis
Background/Purpose: Synovial fibroblasts play crucial roles in the pathogenesis of rheumatoid arthritis (RA). They expand as part of the pannus, mediate degradation of cartilage, amplify…Abstract Number: 2137 • 2015 ACR/ARHP Annual Meeting
Critical Role of Fibroblast-like Synoviocytes Glycolytic Metabolism in Rheumatoid Arthritis
Background/Purpose: Glucose metabolism is altered not only in tumor cell growth but also in immune cells on activation. However, little is known about glucose metabolism…Abstract Number: 2138 • 2015 ACR/ARHP Annual Meeting
Safety and Efficacy Results of a Phase 2, Double-Blind, Placebo-Controlled Clinical Study of Duvelisib with Background Methotrexate (MTX) in Adults with Moderate-to-Severe Rheumatoid Arthritis (RA)
Background/Purpose: Duvelisib is a potent, oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-δ,γ being developed for hematologic malignancies, and was also explored in early phase studies in…Abstract Number: 2139 • 2015 ACR/ARHP Annual Meeting
Results of a Phase 1b/2a Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XmAb®5871 in Patients with Rheumatoid Arthritis (RA)
Background/Purpose: XmAb®5871 is a humanized Fc engineered monoclonal antibody that binds to the B cell restricted surface antigen CD19 and has enhanced Fc binding to…Abstract Number: 2140 • 2015 ACR/ARHP Annual Meeting
Drug Specific Risk and Associated Factors for Vasculitis-like Events in Patients Exposed to Tumour Necrosis Factor-α Inhibitor Therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Background/Purpose: The association between TNF inhibitors (TNFis) and vasculitis-like events, possibly secondary to induction of autoantibodies, has been well reported. However, the incidence, drug-specific differences…Abstract Number: 2141 • 2015 ACR/ARHP Annual Meeting
Risk of Cancer in Non-TNFi Biologics-Treated RA
Background/Purpose: Immune incompetence may lower host surveillance against incipient tumours. Conversely, immune therapies have emerged as a promising therapeutic approach to cancer. Malignancies thus constitute…Abstract Number: 2142 • 2015 ACR/ARHP Annual Meeting
Comparison of Interferon-y Release Assay Versus Tuberculin Skin Test in the Golimumab UC and the Golimumab SC Rheumatology (RA, PsA, and AS) Clinical Study Programs
Background/Purpose: Interferon-ƴ release assays (IGRAs) offer the possibility of an improved method to detect TB infections in pts with autoimmune disorders. Compare results of…Abstract Number: 2143 • 2015 ACR/ARHP Annual Meeting
A Safety Analysis of Tofacitinib 5mg Twice Daily Administered As Monotherapy or in Combination with Background Conventional Synthetic Dmards in a Phase 3 Rheumatoid Arthritis Population
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). In Phase 3 (P3) studies, tofacitinib demonstrated safety and efficacy…Abstract Number: 2144 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Different Dose Regimens of a Selective IL-23p19 Inhibitor (BI 655066) Compared with Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis with and without Psoriatic Arthritis
Background/Purpose: IL-23 is essential for the differentiation and maintenance of Th17 cells in psoriasis and psoriatic arthritis (PsA). We assessed the efficacy and safety of…Abstract Number: 2145 • 2015 ACR/ARHP Annual Meeting
Ixekizumab Improves Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis
Background/Purpose: Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease associated with psoriasis, peripheral arthritis, enthesitis, dactylitis, and spondylitis. PsA has a significant negative impact…Abstract Number: 2146 • 2015 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis in Anti-TNF-Naive Patients and Those Previously Exposed to Anti-TNF Therapy: 52-Week Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial with Subcutaneous Dosing
Background/Purpose: There remains an unmet need for additional treatment options for patients (pts) with psoriatic arthritis (PsA) who have had an inadequate response to or…Abstract Number: 2147 • 2015 ACR/ARHP Annual Meeting
The Effect of Sulfasalazine and Methotrexate on the Immunogenicity of Infliximab and Adalimumab in Patients with Spondyloarthritis
Background/Purpose: Classic DMARDs are not routinely prescribed for axial spondyloarthritis (SpA). Recent studies have found that concomitant therapy with methotrexate (MTX) reduced immunogenicity of TNF…Abstract Number: 2148 • 2015 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvements in Psoriatic Arthritis: 2-Year Efficacy and Safety Results from a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial
Background/Purpose: In the Phase 3, randomized, double-blind, placebo (PBO)-controlled, FUTURE 1 study (NCT01392326), the anti–interleukin-17A monoclonal antibody secukinumab provided rapid and significant improvements in key…
ACR Meeting Abstracts